Augmentin BD

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Augmentin BD

Property Description
Active ingredients Amoxicillin, Clavulanic Acid
Form Tablet, Oral suspension
Pharmacological class beta-Lactam Antibiotic (Penicillin)
Common use Combats bacterial infections
Origin Semi-synthetic combination

Augmentin BD is the commercial name for the prescription-only medicine known generically as Co-amoxiclav or Amoxicillin/Clavulanic Acid. It is an antibiotic belonging to the Penicillins class within the beta-Lactam group. Its primary purpose is to combat bacterial infections that are susceptible to its action. The BD designation, meaning bis in die (twice daily), indicates this differentiated formulation is designed for simple, oral administration two times per day, a regimen clinically recognized for promoting patient adherence and consistent drug exposure.

This medicine is a fixed-dose combination product containing two essential active ingredients: the antibiotic Amoxicillin and the beta-Lactamase inhibitor Clavulanic Acid. The combination is considered an Access group antibiotic, supporting its use for common infections. The combination is utilized because it extends the spectrum of the antibiotic against resistance. This means the combination helps the antibiotic work against bacteria that would otherwise be able to destroy it.

The formulation utilizes a synergistic advantage to address microbial defenses. The Amoxicillin component is responsible for the bactericidal action, while Clavulanic Acid serves a crucial protective role, neutralizing beta-lactamase enzymes produced by resistant bacteria. This combined action results in spectrum broadening, making the medicine effective for pathogen eradication. The availability of both tablet and oral suspension forms is a distinctive feature ensuring that this treatment can be administered to a diverse target audience, including both adult and pediatric patients.

What side effects are possible with Augmentin BD?

Possible side effects and safety information

The safety profile for Amoxicillin/Clavulanic Acid is organized by System-Organ Class and documented frequency, based on official regulatory data. Adverse reactions primarily involve the gastrointestinal system and the skin.

Frequency Category Common Side Effects (Examples)
Very Common Diarrhea
Common Nausea, Vomiting, Mucocutaneous candidosis
Uncommon Headache, Dizziness, Skin rash, Indigestion, moderate increases in liver enzymes (AST/ALT)

Serious Adverse Reactions officially listed in regulatory labeling include severe hypersensitivity reactions such as anaphylaxis and angioneurotic oedema. Severe cutaneous adverse reactions, including Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are also documented as rare possibilities. Hepatic dysfunction, including cholestatic jaundice and hepatitis, may be severe and has been reported, sometimes occurring several weeks after treatment has ceased.

Safety notes specify that gastrointestinal effects like nausea are more common with higher oral dosages. The medicine is contraindicated in patients with a history of liver problems (cholestatic jaundice or hepatic impairment) associated with prior use of Amoxicillin/Clavulanic Acid or a history of serious allergic reactions to penicillins. Caution is required, and dosage adjustments are necessary, for patients with renal impairment. The possibility of overgrowth of non-susceptible organisms should be kept in mind during prolonged therapy.

Overdose and Emergency Response

Overdosage with Augmentin BD (Amoxicillin/Clavulanic Acid) is officially documented to present with characteristic manifestations primarily affecting the gastrointestinal system, including severe abdominal pain, vomiting, and diarrhea. This acute presentation may result in a disturbance of the fluid and electrolyte balance.

More serious outcomes officially recognized in regulatory labeling include central nervous system excitation and convulsions, particularly noted with high drug exposure or in cases of impaired renal function. A critical, documented complication of overdosage is crystalluria, which has the potential to lead to acute renal failure. The risk of crystalluria is specifically relevant in the management of overdose in pediatric patients.

Official regulatory guidance is explicit: immediate medical attention must be sought in all cases of suspected overdosage. Management is described as strictly symptomatic and supportive. While no specific antidote is known, regulatory documents confirm that the active components are effectively removed from the circulation via hemodialysis.

Therapeutic Uses of Augmentin BD

What Augmentin BD Treats: Main Uses and Benefits

Augmentin BD (amoxicillin/clavulanic acid) is commonly used to help manage a wide range of bacterial infections, relevant in contexts where bacteria may be resistant to the penicillin family. This difference in therapeutic action may assist with managing the infection and contributes to easing painful, disruptive symptoms across several body systems. This medicine is relevant across multiple therapeutic domains.

It is relevant for easing symptoms related to acute infections of the respiratory tract (pneumonia, sinusitis), the urinary tract (pyelonephritis), and in conditions of the skin and soft tissues, such as cellulitis and abscesses. The medicine is applied when symptoms intensify, and supportive relief is appropriate for addressing systemic fever, localized pain, and functional strain.

“This therapeutic support assists patients by easing discomfort and helping to maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: Symptom Management Contexts

Augmentin BD is used across diverse patient groups, including pediatric patients, when symptoms cluster into patterns requiring short-term symptomatic assistance. It supports the patient during difficult episodes by easing the symptom burden from both generalized illness and localized inflammation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Augmentin BD?

The official eligibility for Augmentin BD (Amoxicillin/Clavulanic Acid) is strictly defined by regulatory bodies and must align with a patient’s health profile and age.

Absolute Non-Eligibility (Contraindications)

Use is prohibited for patients with a documented history of serious hypersensitivity (allergic reaction) to any penicillin or other beta-lactam antibiotic. The medicine is also contraindicated for individuals who have previously experienced cholestatic jaundice or hepatic dysfunction linked to its use.

Restricted and Conditional Use

  • Comorbidity: Use should be avoided in patients with known or suspected Infectious Mononucleosis.
  • Organ Function: Patients with hepatic impairment require use with caution and monitoring of liver function. Those with renal impairment necessitate a mandated dose adjustment; certain high-strength tablets are ineligible for severe renal impairment/hemodialysis patients.
  • Age and Weight: Eligibility is established for adults and children 12 weeks of age. Tablets are not recommended for children weighing less than 40 kg, requiring the oral suspension formulation instead.
  • Pregnancy Status: The official label advises that use during pregnancy should occur only if clearly needed. Caution is advised during breastfeeding.

What should I know about interactions with other medicines?

The interaction profile for Augmentin BD (amoxicillin/clavulanic acid) details several pharmacokinetic and pharmacodynamic relationships with other substances, as documented in official regulatory sources. All interaction information is presented at a high, regulatory-aligned descriptive level.

Interactions Affecting Drug Exposure and Clearance Co-administration with Probenecid is documented to inhibit the renal tubular secretion of the Amoxicillin component, resulting in increased and prolonged plasma concentrations of Amoxicillin. Regulatory information also states that the medicine reduces the excretion of Methotrexate, a formal outcome that may lead to an increase in Methotrexate toxicity.

Interactions Affecting Co-medication Efficacy and Risk When co-administered with Oral Anticoagulants, there is a documented risk of prolongation of prothrombin time (INR). Use with Combined Oral Contraceptives may reduce the contraceptive efficacy by hindering the intestinal reabsorption of the estrogen component. Furthermore, co-administration with Allopurinol is associated with an increased incidence of allergic skin reactions or rash.

Specific Use Restrictions and Dietary Notes Regulatory documents state that co-administration must be avoided in patients with Infectious Mononucleosis due to the significantly increased risk of a morbilliform rash. Absorption of the Clavulanate component is generally documented as greater when taken with food compared to a fasted state, a specific condition noted in the official prescribing information.

Mechanism of Action

How Augmentin BD Works

Augmentin BD provides a dual mechanism of action that targets bacterial components. The first component, amoxicillin, is a beta-lactam antibiotic that competitively and irreversibly inhibits bacterial transpeptidases (also known as penicillin-binding proteins or PBPs). This inhibition prevents the cross-linking of peptidoglycan polymers, which is required for bacterial cell wall synthesis, resulting in bacterial cell lysis.

The second component, clavulanic acid, is a beta-lactamase inhibitor. beta-lactamase enzymes, produced by certain bacteria, hydrolyze the beta-lactam ring of amoxicillin, causing inactivation. Clavulanic acid binds covalently to the active site of these beta-lactamase enzymes, inactivating them. This key inhibition allows amoxicillin to remain intact and successfully bind to PBPs.

Dosage and Administration Information

Augmentin BD (Amoxicillin/Clavulanic Acid) is administered by the oral route using film-coated tablets or reconstituted oral suspension. The BD (Bis in Die, or twice daily) designation reflects the primary, officially recommended dosing frequency.

Administration and Timing

To optimize the absorption of clavulanate potassium and help minimize potential gastrointestinal intolerance, the medicine should be taken at the start of a meal. The tablets should be swallowed whole; the oral suspension requires reconstitution with water and must be shaken well before each use.

Official Dosing and Duration

Dosing is based on the amoxicillin component.

Population Standard BD Regimen Maximum Duration
Adults (≥40 kg) 500 mg or 875 mg (amoxicillin component) every 12 hours Not exceeding 14 days without review
Pediatric Patients Dosing is based on weight (mg/kg/day), typically divided every 12 hours Not exceeding 14 days without review

Dosage Adjustments

Dosage adjustments are required for patients with impaired kidney function (renal impairment). The 875 mg dose of the amoxicillin component must not be used if the patient's creatinine clearance (CrCl) is below 30 mL/min. For patients with severe renal impairment (CrCl < 10 mL/min), the dose is reduced to be given once every 24 hours. Patients undergoing hemodialysis require an additional dose administered during or at the end of the procedure. Monitoring of hepatic function at regular intervals is recommended when dosing patients with hepatic impairment.

Recent Clinical Evidence

Augmentin BD: Recent Clinical Evidence

Augmentin BD is a twice-daily formulation of amoxicillin and clavulanate potassium, combining an antibiotic with a beta-lactamase inhibitor. Clinical research has primarily focused on validating its efficacy and safety profile compared to older, three-times-daily (t.d.s.) regimens, especially in the treatment of common bacterial infections.

Comparison of Dosing Regimens

Key studies have investigated the twice-daily (b.d.) formulation in comparison to the standard t.d.s. dosing for the treatment of respiratory tract infections. A large, double-blind study examining patients with lower respiratory tract infection (LRTI) found that the b.d. regimen (875/125 mg) demonstrated similar clinical and bacteriological success rates to the t.d.s. regimen (500/125 mg). The study also noted that fewer patients in the b.d. group reported moderate or severe diarrhea.

Similarly, research into pediatric acute otitis media (AOM) has established that the b.d. amoxicillin/clavulanate regimen (45/6.4 mg/kg/day) provides equivalent efficacy to the t.d.s. formulation.

Focus on Specific Infections

Evidence from clinical trials supports the use of amoxicillin/clavulanate for infections caused by beta-lactamase-producing bacteria, which are often resistant to amoxicillin alone. The established indications for the drug, supported by clinical data, include:

  • Lower and Upper Respiratory Tract Infections (e.g., acute bacterial otitis media, sinusitis, pneumonia)
  • Skin and Skin Structure Infections
  • Urinary Tract Infections

Recent analysis also continues to explore its role in the empirical treatment of Community-Acquired Pneumonia (CAP), with various clinical guidelines including it as a primary therapeutic option.

Frequently Asked Questions (FAQ)

Common questions about Augmentin BD (FAQ)

Q: Why does Augmentin BD often cause diarrhea or stomach upset?

A: Diarrhea is listed as a very common side effect in the official product information. This common occurrence is believed to be linked to the medicine's effect on the balance of natural bacteria (gut flora) in the intestines, a mechanism frequently observed with many antibiotic treatments.

Q: What should I know about taking Augmentin BD if I have a history of liver problems?

A: The medicine is described as contraindicated (meaning it should not be used) if there is a history of liver problems, such as cholestatic jaundice or hepatic dysfunction, related to previous use of this drug combination. For existing liver impairment, regulatory information notes that caution is required, and the monitoring of liver function is recommended by official bodies during therapy.

Q: Can Augmentin BD interact with birth control pills (oral contraceptives)?

A: Regulatory documents describe that Augmentin BD may reduce the effectiveness of combined oral contraceptives. This potential interaction is thought to occur because the antibiotic component can interfere with the reabsorption of the estrogen component in the intestine.

Q: Does Augmentin BD interact with blood thinners like warfarin?

A: Official information states that co-administration with oral anticoagulants (e.g., warfarin) carries a potential risk. This use may result in the prolongation of prothrombin time (an increased INR), which may necessitate monitoring.

Q: What is the risk of having a relapse of the infection if I stop treatment too soon?

A: Official sources indicate that not completing the full course of therapy may decrease the overall effectiveness of the treatment and may increase the likelihood of bacteria developing resistance to the medicine.

Q: Is Augmentin BD considered a 'strong' antibiotic compared to Amoxicillin alone?

A: Regulatory documents explain that the purpose of combining amoxicillin with clavulanic acid is to extend the antibiotic's spectrum of activity. Clavulanic acid helps the amoxicillin work against certain bacteria that are otherwise resistant to amoxicillin alone, effectively broadening its use against a wider range of pathogens.

Q: What types of infections is Augmentin BD most commonly prescribed to treat?

A: According to official indications, the medicine is used for treating bacterial infections in various parts of the body. These include lower respiratory tract infections, acute bacterial otitis media (ear infection), sinusitis, skin structure infections, and infections of the urinary tract.

Q: What is the longest time I can safely take Augmentin BD for an infection?

A: This medicine is intended for short-term use. The officially recommended maximum treatment duration generally does not exceed 14 days without a medical review.

Q: Is it normal to feel tired or fatigued while taking Augmentin BD?

A: While feeling mild tiredness is not listed as a common side effect, official documents mention that unusual weakness or fatigue is a possible sign of a serious side effect, such as a liver problem. Symptoms like unusual or severe fatigue are often included in regulatory documents as a signal to look out for.

Q: Are there ways to reduce stomach side effects like nausea while taking Augmentin BD?

A: Official prescribing information states the medicine is to be taken at the start of a meal. This practice is suggested to help optimize absorption of one component and to specifically help minimize the potential for gastrointestinal intolerance like nausea.

Q: Can Augmentin BD cause a yeast infection (thrush) in the mouth or genital area?

A: Mucocutaneous candidosis, which is the medical term for a yeast infection or thrush, is listed as a common side effect in official safety information. This is another result of the antibiotic affecting the natural balance of microorganisms in the body.

Q: Are there any dietary supplements or vitamins that interact with Augmentin BD?

A: Official data indicates that interactions have been documented with certain probiotic supplements, such as those containing Lactobacillus. The antibiotic component may decrease the effects of the probiotic if they are taken at the same time.

Q: Is it necessary to take Augmentin BD at the exact same time every day?

A: The medicine is prescribed to be taken twice daily (e.g., every 12 hours) to maintain consistent levels in the body, which implies the timing is important. Instructions for a missed dose are provided in patient information to guide patients on managing the timing if an irregularity occurs.

Q: Can alcohol be consumed safely while taking Augmentin BD?

A: Regulatory information indicates there is no known direct interaction between the medicine and alcohol. However, official safety notes suggest that consuming alcohol may potentially increase the risk of experiencing certain side effects like nausea, vomiting, and liver problems.

Q: Is it acceptable to crush or split Augmentin BD tablets?

A: The tablets are specifically designed to be swallowed whole to ensure proper delivery of the medicine. For patients who have difficulty swallowing, the oral suspension (liquid) formulation is the appropriate alternative.

Q: What is antibiotic resistance, and how does Augmentin BD relate to it?

A: The regulatory label addresses antibiotic resistance as a reason to use the medicine only when it is needed. Augmentin BD's unique combination of amoxicillin and clavulanic acid helps it work against certain bacteria that are otherwise resistant to amoxicillin alone, thereby fighting resistance mechanisms.

Q: Can Augmentin BD affect the results of certain laboratory tests (e.g., urine glucose)?

A: Yes, official safety information notes that the medicine may cause false-positive results when testing for the presence of glucose (sugar) in urine if using certain specific, non-enzymatic tests. It may also result in a false positive Coombs test.

Q: Why is it important for patients with phenylketonuria (PKU) to check the ingredients of the liquid form?

A: This warning is present because some liquid suspension formulations may contain phenylalanine (a component of aspartame). This requires caution for patients with the metabolic condition phenylketonuria (PKU), who must restrict their intake of this substance.

Q: Does Augmentin BD have a warning about a serious reaction called Drug-induced Enterocolitis Syndrome (DIES)?

A: Yes. Drug-induced enterocolitis syndrome (DIES) is a specific, severe reaction listed in the Warnings and Precautions section of the drug's regulatory label.

Q: What is the recommended storage temperature for Augmentin BD tablets or suspension?

A: Tablets should be stored in the original packaging at room temperature (typically below 25 C or 30 C) and protected from moisture. However, the reconstituted suspension must be stored under refrigeration (2 C to 8 C) and must not be frozen.

Q: Is it possible for a rare side effect to show up days or weeks after finishing the course of Augmentin BD?

A: Yes, official safety information indicates that a rare, serious side effect, specifically hepatic dysfunction (liver problems), may occur and has been reported, sometimes developing several weeks after the treatment has been stopped.

Q: Are there any special warnings for people who have a history of seizures and take Augmentin BD?

A: Seizures are listed as a rare side effect in official safety information. This warning is noted under the central nervous system effects of the medicine.

Q: What should I do if I forget to take a dose of Augmentin BD?

A: Patient information includes instructions to take the missed dose as soon as it is remembered. However, if it is close to the time of the next scheduled dose, the missed dose should be skipped entirely. A double dose must not be taken.

Q: Can Augmentin BD cause temporary tooth discoloration in children?

A: A change in tooth color (often described as yellow, gray, or brown) has been reported in regulatory documents, mainly in children. This discoloration is usually described as being temporary and can often be reduced or removed with brushing or dental cleaning.

Q: What is the specific reason for the mandatory dose adjustment in renal impairment?

A: The dose adjustment is mandated because the kidneys are primarily responsible for eliminating the components of the medicine from the body. Impaired kidney function may lead to increased and prolonged drug concentrations.

Q: Can Augmentin BD cause behavior changes or mood swings in children?

A: Official safety information lists nervous system effects such as anxiety, irritability, and restlessness among the rare side effects.

Q: Is a skin rash while taking Augmentin BD always a sign of a serious allergy?

A: Official safety information lists a simple skin rash as an uncommon side effect that is not always allergic. However, a rash accompanied by signs of a severe reaction, such as hives, swelling of the face/throat, or difficulty breathing, is a sign of a serious allergic reaction that requires immediate attention.

Q: Can Augmentin BD cause the onset of a specific type of diaper rash in babies?

A: Official safety information lists mucocutaneous candidosis (thrush/yeast infection) as a common side effect. This condition involves the overgrowth of yeast and is a known cause of diaper rash in babies.

How should Augmentin BD be stored and disposed of?

Storage and Disposal Conditions for Augmentin BD

The required storage conditions for Augmentin BD (Amoxicillin and Clavulanate Potassium) are specific to the formulation (tablet or suspension).


Storage Requirements

  • Tablets: Must be stored in the original container to provide protection from moisture and light. Storage should be at controlled room temperature, typically below 25 C or 30 C.
  • Reconstituted Oral Suspension: Must be stored under refrigeration (2 C to 8 C) and must not be frozen. The suspension must be discarded after 10 days.

Handling and Disposal

All forms of the medicine must be kept out of the sight and reach of children.

Disposal of unused or expired Augmentin BD must be done according to local requirements and must not be thrown away via wastewater (e.g., sink or toilet).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Augmentin BD found in:

A-Z Index: